Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest

ADAPTIVE BIOTECHNOLOGIES CORPORATION Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of -$153.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2026-08-04

  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$153.00K, a 828.57% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was $18.00K, a 18.18% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was $0.00.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$1.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2025 was $42.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2024 was -$103.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2023 was -$54.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2022 was -$177.00K.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month
2026-06-30-$153.00K
10-Q · filed 2026-08-04
-$135.00K
10-Q · filed 2026-08-04
-$135.00K
derived: sum of 3 quarters · filed 2026-08-04
-$136.00K
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$18.00K
10-Q · filed 2026-05-05
$18.00K
derived: sum of 2 quarters · filed 2026-05-05
$17.00K
derived: sum of 3 quarters · filed 2026-05-05
$38.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$1.00K
derived: sum of 2 quarters · filed 2026-02-26
$20.00K
derived: sum of 3 quarters · filed 2026-08-04
$42.00K
10-K · filed 2026-02-26
2025-09-30-$1.00K
10-Q · filed 2025-11-05
$20.00K
derived: sum of 2 quarters · filed 2026-08-04
$42.00K
10-Q · filed 2025-11-05
$17.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$21.00K
10-Q · filed 2026-08-04
$43.00K
10-Q · filed 2026-08-04
$18.00K
derived: sum of 3 quarters · filed 2026-08-04
-$8.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$22.00K
10-Q · filed 2026-05-05
-$3.00K
derived: sum of 2 quarters · filed 2026-05-05
-$29.00K
derived: sum of 3 quarters · filed 2026-05-05
-$55.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$25.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$51.00K
derived: sum of 2 quarters · filed 2026-02-26
-$77.00K
derived: sum of 3 quarters · filed 2026-02-26
-$103.00K
10-K · filed 2026-02-26
2024-09-30-$26.00K
10-Q · filed 2025-11-05
-$52.00K
derived: sum of 2 quarters · filed 2025-11-05
-$78.00K
10-Q · filed 2025-11-05
-$104.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$26.00K
10-Q · filed 2025-08-05
-$52.00K
10-Q · filed 2025-08-05
-$78.00K
derived: sum of 3 quarters · filed 2026-02-26
-$104.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$26.00K
10-Q · filed 2025-05-01
-$52.00K
derived: sum of 2 quarters · filed 2026-02-26
-$78.00K
derived: sum of 3 quarters · filed 2026-02-26
-$79.00K
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$26.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$52.00K
derived: sum of 2 quarters · filed 2026-02-26
-$53.00K
derived: sum of 3 quarters · filed 2026-02-26
-$54.00K
10-K · filed 2026-02-26
2023-09-30-$26.00K
10-Q · filed 2024-11-07
-$27.00K
derived: sum of 2 quarters · filed 2024-11-07
-$28.00K
10-Q · filed 2024-11-07
-$69.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30-$1.00K
10-Q · filed 2024-08-01
-$2.00K
10-Q · filed 2024-08-01
-$43.00K
derived: sum of 3 quarters · filed 2025-03-03
-$81.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31-$1.00K
10-Q · filed 2024-05-07
-$42.00K
derived: sum of 2 quarters · filed 2025-03-03
-$80.00K
derived: sum of 3 quarters · filed 2025-03-03
-$118.00K
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31-$41.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
-$79.00K
derived: sum of 2 quarters · filed 2025-03-03
-$117.00K
derived: sum of 3 quarters · filed 2025-03-03
-$177.00K
10-K · filed 2025-03-03
2022-09-30-$38.00K
10-Q · filed 2023-11-09
-$76.00K
derived: sum of 2 quarters · filed 2023-11-09
-$136.00K
10-Q · filed 2023-11-09
-$60.00K
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30-$38.00K
10-Q · filed 2023-08-02
-$98.00K
10-Q · filed 2023-08-02
-$22.00K
derived: sum of 3 quarters · filed 2024-02-29
-$117.00K
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$60.00K
10-Q · filed 2023-05-03
$16.00K
derived: sum of 2 quarters · filed 2024-02-29
-$79.00K
derived: sum of 3 quarters · filed 2024-02-29
2021-12-31$76.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
-$19.00K
derived: sum of 2 quarters · filed 2024-02-29
-$19.00K
10-K · filed 2024-02-29
2021-09-30-$95.00K
10-Q · filed 2022-11-03
-$95.00K
10-Q · filed 2022-11-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B